Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Journal of Clinical Investigation

• Publication date

  1991-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1172/JCI115272PMID 1647414PMCID PMC295996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statistical analysis of enzyme kinetic data.

  2006cited by this paper
• Effects of Amrinone and Enoximone on the Subclasses of Cyclic AMP Phosphodiesterase from Human Heart and Kidney

  1990cited by this paper
• Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation.

  1990cited by this paper
• Phospholamban-mediated stimulation of Ca2+ uptake in sarcoplasmic reticulum from normal and failing hearts.

  1990cited by this paper
• Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium.

  1989cited by this paper
• Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart

  1989cited by this paper
• Phosphodiesterase isozyme inhibition, activation of the cAMP system, and positive inotropy mediated by milrinone in isolated guinea pig cardiac muscle.

  1989cited by this paper
• Ca2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy.

  1989cited by this paper
• Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478), in guinea-pig hearts

  1988cited by this paper
• Subsensitivity of the Failing Human Heart to Isoprenaline and Milrinoneo is Related to β‐Adrenoceptor Downregulation

  1988cited by this paper
• Multiple isozymes of cyclic nucleotide phosphodiesterase.

  1988cited by this paper
• Subcellular Distribution of High‐Affinity Type IV Cyclic AMP Phosphodiesterase Activity in Rabbit Ventricular Myocardium: Relations to the Effects of Cardiotonic Drugs

  1988cited by this paper
• Assay of cyclic nucleotide phosphodiesterase using radiolabeled and fluorescent substrates.

  1988cited by this paper
• Computer programs for calculating total from specified free or free from specified total ionic concentrations in aqueous solutions containing multiple metals and ligands.

  1988cited by this paper
• Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets.

  1988cited by this paper
• Multiple isozymes of cyclic nucleotide phosphodiesterase.

  1988cited by this paper
• Subclasses of Cyclic AMP‐Specific Phosphodiesterase in Left Ventricular Muscle and Their Involvement in Regulating Myocardial Contractility

  1987cited by this paper
• The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.

  1987cited by this paper
• Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure.

  1987cited by this paper
• Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.

  1986cited by this paper
• β1‐ and β2‐Adrenergic‐Receptor Subpopulations in Nonfailing and Failing Human Ventricular Myocardium: Coupling of Both Receptor Subtypes to Muscle Contraction and Selective β1‐Receptor Down‐Regulation in Heart Failure

  1986cited by this paper
• Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.

  1986cited by this paper
• LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum.

  1986cited by this paper
• Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.

  1986cited by this paper
• Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase.

  1984cited by this paper
• Pharmacology and inotropic potential of forskolin in the human heart.

  1984cited by this paper
• Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes.

  1983cited by this paper
• Biochemical Studies on the Mechanism of Cardiotonic Activity of MDL 17,043

  1982cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• A rapid method of total lipid extraction and purification.

  1959cited by this paper
• Microdetermination of Phosphorus

  1956cited by this paper

• Nanodomain cAMP signalling in cardiac pathophysiology: potential for developing targeted therapeutic interventions.

  2024cites this paper
• Abnormal phosphorylation / dephosphorylation and Ca2+ dysfunction in heart failure

  2024cites this paper
• Clinical pharmacology of cardiac cyclic AMP in human heart failure: too much or too little?

  2023cites this paper
• Phosphodiesterase in heart and vessels: from physiology to diseases

  2023cites this paper
• It takes two to tango: cardiac fibroblast-derived NO-induced cGMP enters cardiac myocytes and increases cAMP by inhibiting PDE3

  2023cites this paper
• PDE4DIP in health and diseases.

  2022cites this paper
• Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts

  2022cites this paper
• Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure

  2022cites this paper
• Selective changes in cytosolic β-adrenergic cAMP signals and L-type Calcium Channel regulation by Phosphodiesterases during cardiac hypertrophy.

  2020cites this paper
• Adrenergic Receptor Signaling in Heart Failure

  2020cites this paper
• The cardiovascular effects of xanthines and selective PDE inhibitors: a risk–benefit analysis

  2020cites this paper
• Functions of PDE3 Isoforms in Cardiac Muscle

  2018cites this paper
• cAMP Compartmentalisation and Hypertrophy of the Heart: ‘Good’ Pools of cAMP and ‘Bad’ Pools of cAMP Coexist in the Same Cardiac Myocyte

  2017cites this paper
• Computational Modeling of Cyclic Nucleotide Signaling Mechanisms in Cardiac Myocytes

  2017cites this paper
• Myocardial Response to Milrinone in Single Right Ventricle Heart Disease.

  2016cites this paper
• Age-Related Differences in Phosphodiesterase Activity and Effects of Chronic Phosphodiesterase Inhibition in Idiopathic Dilated Cardiomyopathy

  2015influential citation
• Carvedilol induces greater control of β2- than β1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium

  2014cites this paper
• Resveratrol Attenuates the Development of Trans-Aortic Constriction (TAC) Induced Heart Failure in Mice

  2013cites this paper
• PDE3, but not PDE4, reduces β1‐ and β2‐adrenoceptor‐mediated inotropic and lusitropic effects in failing ventricle from metoprolol‐treated patients

  2013influential citation
• PDE4 in the human heart – major player or little helper?

  2013influential citation
• Phosphodiesterases and subcellular compartmentalized cAMP signaling in the cardiovascular system.

  2012cites this paper
• Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes

  2012cites this paper
• PDE3 inhibition in dilated cardiomyopathy.

  2011cites this paper
• Phosphodiesterase inhibition in heart failure.

  2011cites this paper
• Differential regulation of β2‐adrenoceptor‐mediated inotropic and lusitropic response by PDE3 and PDE4 in failing and non‐failing rat cardiac ventricle

  2011cites this paper
• MRP4 in cardiac myocytes

  2011cites this paper
• Conserved expression and functions of PDE4 in rodent and human heart

  2010cites this paper
• Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition.

  2010cites this paper
• Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure.

  2010cites this paper
• Phosphodiesterase inhibition in heart failure

  2009cites this paper
• Decreased Expression and Activity of cAMP Phosphodiesterases in Cardiac Hypertrophy and Its Impact on &bgr;-Adrenergic cAMP Signals

  2009cites this paper
• THE ROLE OF PHOSPHODIESTERASES IN CYCLIC NUCLEOTIDE COMPARTMENTATION ACROSS DIFFERENT SIGNALLING PATHWAYS IN THE ADULT RAT VENTRICULAR MYOCYTE

  2009cites this paper
• The Role of Phosphodiesterases in Cyclic Nucleotide Compartmentation Across Different Pathways in the Adult Rat Ventricular Myocyte

  2009cites this paper
• 5‐HT4‐elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles

  2008influential citation
• Kontinuierliche β-Blockade mit Esmolol in Kombination mit Enoximon-Gabe

  2008cites this paper
• Intravenous inotropic agents in heart failure.

  2008cites this paper
• Myocardial Phosphodiesterases and Regulation of Cardiac Contractility in Health and Cardiac Disease

  2007cites this paper
• Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart Overview of Phosphodiesterases and Their Regulation cAMP and cGMP Signaling Crosstalk: Role of Phosphodiest

  2007cites this paper
• Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure

  2007cites this paper
• Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.

  2007cites this paper
• Cyclic Nucleotide Phosphodiesterase PDE1C1 in Human Cardiac Myocytes*

  2007cites this paper
• Cardiac hypertrophy diminished the effects of isoproterenol on delayed rectifier potassium current in rat heart.

  2006cites this paper
• Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle

  2006cites this paper
• Arterial baroreflex sensitivity is a good predictor of inotropic responses to a phosphodiesterase inhibitor in human heart failure

  2006cites this paper
• A Specific Pattern of Phosphodiesterases Controls the cAMP Signals Generated by Different Gs-Coupled Receptors in Adult Rat Ventricular Myocytes

  2006cites this paper
• Phosphodiesterase 4D is required for beta2 adrenoceptor subtype-specific signaling in cardiac myocytes.

  2005cites this paper
• Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3 and Their Contribution to cAMP Hydrolytic Activity in Subcellular Fractions of Human Myocardium*

  2005cites this paper
• Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats.

  2005cites this paper
• Rationale and design of the enoximone clinical trials program.

  2005cites this paper
• Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy.

  2005cites this paper
• Fluorescence Resonance Energy Transfer–Based Analysis of cAMP Dynamics in Live Neonatal Rat Cardiac Myocytes Reveals Distinct Functions of Compartmentalized Phosphodiesterases

  2004cites this paper
• Comparision of the Inotropic Effects of Levosimendan, Rolipram, and Dobutamine on Human Atrial Trabeculae

  2004cites this paper
• Fluorescence Resonance Energy Transfer–Based Analysis of cAMP Dynamics in Live Neonatal Rat Cardiac Myocytes Reveals Distinct Functions of Compartmentalized Phosphodiesterases Cellular Biology

  2004cites this paper
• Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure.

  2003cites this paper
• β-Adrenergic Receptors and Phosphodiesterase: Present and Future Perspectives

  2003cites this paper
• Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure

  2002influential citation
• Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes.

  2001cites this paper
• Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure

  2001influential citation
• Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving β-blocking agents

  2001cites this paper
• Expression of Phosphodiesterase 4D (PDE4D) Is Regulated by Both the Cyclic AMP-dependent Protein Kinase and Mitogen-activated Protein Kinase Signaling Pathways

  2000cites this paper
• Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure

  2000cites this paper
• Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group.

  2000cites this paper
• Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues.

  2000cites this paper
• Inotropes in the beta‐blocker era

  2000cites this paper
• Down regulation of myocardial β1-adrenoceptor signal transduction system in pacing-induced failure in dogs with aortic stenosis-induced left ventricular hypertrophy

  2000cites this paper
• Heterotrimeric G proteins in heart disease.

  2000cites this paper
• Pathophysiologie der chronischen Herzinsuffizienz

  2000cites this paper
• Heterotrimeric G proteins in heart disease 1

  2000cites this paper
• Definition und Epidemiologie der chronischen Herzinsuffizienz

  2000cites this paper
• Klinik und Symptomatologie der chronischen Herzinsuffizienz

  2000cites this paper
• Akute kardiale Dyspnoe und Lungenödem

  2000cites this paper
• Best Practices for Optimally Treated Advanced Heart Failure

  2000cites this paper
• Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei.

  1999cites this paper
• Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure.

  1999cites this paper
• Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure

  1999cites this paper
• Mechanisms of desensitization to a PDE inhibitor ( milrinone ) in conscious dogs with heart failure

  1999cites this paper
• Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate.

  1999cites this paper
• Myocardial effects of cyclic AMP phosphodiesterase inhibition are dampened in thyroxine-induced cardiac hypertrophy.

  1998cites this paper
• cAMP‐Mediated Signal Transduction and Sarcoplasmic Reticulum Function in Heart Failure

  1998cites this paper
• Effect of inotropic interventions on the force-frequency relation in the human heart

  1998cites this paper
• Calcium sequestration by the sarcoplasmic reticulum in heart failure.

  1998cites this paper
• Effects of cyclic adenosine monophosphate (cAMP) on sarcoplasmic reticulum Ca2+-loading in failing rabbit and human cardiac trabeculae

  1998cites this paper
• Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A.

  1997cites this paper
• Cyclic AMP-Mediated Signal Transduction in Heart Failure: Molecular Pathophysiology and Therapeutic Implications

  1997cites this paper
• Positive inotropic therapy: dead end or new horizon?

  1996cites this paper
• Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells.

  1996cites this paper
• 2 – Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods

  1996cites this paper
• 6 – cGMP-Inhibited Phosphodiesterases (PDE3)

  1996cites this paper
• Heterotrimeric G proteins in heart disease.

  1996cites this paper
• Mechanism of action of OPC-8490 in human ventricular myocardium.

  1996cites this paper
• Expression and activity of low Km, cGMP-inhibited cAMP phosphodiesterase in cardiac and skeletal muscle.

  1996cites this paper
• Effect of ryanodine on sarcoplasmic reticulum Ca2+ accumulation in nonfailing and failing human myocardium.

  1995cites this paper
• Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family).

  1995cites this paper
• Is contractility depressed in the failing human heart?

  1995cites this paper
• Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart.

  1995cites this paper
• Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy.

  1994cites this paper
• Ca2+‐Transporting ATPase, Phospholamban, and Calsequestrin Levels in Nonfailing and Failing Human Myocardium

  1994cites this paper
• cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium.

  1994cites this paper
• Ca(2+)-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium.

  1994cites this paper
• Cytosolic and sarcoplasmic reticulum-associated low Km, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium.

  1993cites this paper